Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus.
Post-hoc analysis of the efficacy and safety of ertugliflozin in East/Southeast (E/SE) Asian patients with type 2 diabetes mellitus (T2DM). Efficacy evaluations used data from randomized, double-blind, Phase 3 studies: a pool of two 26-week placebo-controlled studies and one 52-week active comparator (glimepiride) study. Least-squares mean change from baseline was calculated for glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), body weight (BW) and systolic blood pressure (SBP). Safety evaluation included overall and prespecified adverse events based on pooled data (broad pool) from seven Phase 3 studies (including studies in the efficacy analysis). Among 161 E/SE Asian patients in the placebo pool (ertugliflozin n=106), ertugliflozin reduced HbA1c, FPG, BW and SBP from baseline at Week 26. The placebo-adjusted changes from baseline for ertugliflozin 5mg and 15mg were: HbA1c, -0.9% and -1.0%; BW, -2.1kg and -1.9kg; SBP -3.3mmHg and -3.5mmHg, respectively. Among 174 E/SE Asian patients in the active-comparator study (ertugliflozin n=118), HbA1c changes from baseline at Week 52 were -0.6%, -0.6% and -0.7% for ertugliflozin 5mg, 15mg and glimepiride, respectively. Ertugliflozin 5mg and 15mg reduced BW from baseline by -4.3kg and -4.1kg, respectively, and SBP by -7.4mmHg and -9.3mmHg, respectively, compared with glimepiride. Safety findings were generally consistent with overall ertugliflozin safety data that published to date. Treatment with ertugliflozin was associated with reductions in HbA1c, FPG, BW and SBP and was generally well tolerated in E/SE Asian patients with T2DM. ClinicalTrials.gov identifier: NCT01986855, NCT01999218, NCT01958671, NCT02099110, NCT02036515, NCT02033889, NCT02226003 This article is protected by copyright. All rights reserved.